When it comes to biotech shares in Australia there is one in particular that stands head and shoulders above the rest.
That is of course the $61 billion giant CSL Limited (ASX: CSL). I believe CSL is one of the highest quality companies in Australia and a great buy and hold investment option.
But it's not only biotech that I feel investors should be taking a close look at today. Here are two more exciting biotech shares on my watch list:
The Bionomics Ltd (ASX: BNO) share price has climbed around 6% year-to-date. Investors appear to be snapping up shares thanks to the positive results of its BNC210 anxiety drug's Phase II trials. BNC210 not only outperformed the current standard of care, but also exhibited no signs of sedation, memory impairment, addiction, or loss of motor co-ordination. Whilst it is still early days, if BNC210 lives up to its potential then investors will be rewarded handsomely. Management estimates the global therapeutic market for the treatment of anxiety to be worth US$18.2 billion by 2020.
The Cynata Therapeutics Ltd (ASX: CYP) share price has jumped almost 12% this week thanks to a research note out of Shaw and Partners which rated the regenerative medicine company as a buy with a $1.20 price target. It's not hard to see why its analysts are bullish. Cynata's Cymerus technology can produce an unlimited number of high quality stem cells at a low cost. These can then be used to treat numerous diseases including Graft versus Host Disease (GvHD) and cardiovascular disease. Japanese giant FUJIFILM sees a lot of potential in Cynata and recently bought a 10% stake in the company. As part of the arrangement it has the option to an exclusive worldwide license to market and sell its therapeutic MSC product CYP-001 for the treatment of GvHD. Cynata is definitely worth taking a closer look at today in my opinion.
